1. Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic siRNA delivery in vivo 
Alexander Ewe, Dipl-Chem, Omkar Panchal, MSc, Shashank Reddy Pinnapireddy, MSc, Udo Bakowsky, PhD, Susanne Przybylski, Dipl- Biochem, Achim Temme, PhD, Achim Aigner, PhD 
Nanomedicine: Nanotechnology, Biology and Medicine 
Volume 13, Issue 1, Pages (January 2017)
DOI: /j.nano
Copyright © 2016 Elsevier Inc. Terms and Conditions

2. Figure 1
(A) Electron microscopy analysis of lipopolyplexes, depicting the DPPC lipid component of lipopolyplexes (upper left), polyplexes (upper right), and double-labeled lipopolyplexes (lower panel). See text for details. Bars: 200 nm. (B) DPPC-PEI/siRNA lipopolyplex-mediated survivin knockdown efficacy in PC-3 prostate carcinoma cells, as determined on mRNA (left) and protein level (right). (C) Cell inhibitory effects of lipopolyplex-mediated delivery of siRNAs targeting survivin (siSurv) or mediating cell death (siCD). (D) Absence of cytotoxicity of PEI-based polyplexes and lipopolyplexes, as determined in LDH release assays.
Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2016 Elsevier Inc. Terms and Conditions

3. Figure 2
Lipopolyplex biodistribution upon intraperitoneal administration into mice. (A) Bands of [32P]-labeled, intact siRNA delivered to the indicated organs are shown (three different mice each). Rightmost panel: absence of bands upon delivery of non-complexed siRNA (‘n’); tumor, liver, and spleen are shown as representative examples. (B) Quantitation of lipopolyplex-mediated delivery of radiolabeled siRNA into the indicated organs, adjusted to organ weight.
Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2016 Elsevier Inc. Terms and Conditions

4. Figure 3
(A) Determination of blood serum levels of various markers for hepatotoxicity, cardiac or skeletal muscle damage, impaired kidney function, or acute/chronic inflammation. Mice repeatedly i.p. treated with polyplexes (PP) or lipopolyplexes (LPP) are compared to untreated mice. ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; CREA, serum creatinine; ALB, albumin; GLC, glucose. (B) Absence of immunostimulation at 4 h after i.v. injection of lipopolyplexes into immunocompetent mice. (C) Erythrocyte aggregation assay.
Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2016 Elsevier Inc. Terms and Conditions

5. Figure 4
Lipopolyplex therapy study in mice bearing PC-3 tumor xenografts. (A) Tumor growth kinetics of established tumors upon treatment with DPPC-PEI/siSurv lipopolyplexes (red) vs. negative control (DPPC-PEI/siCtrl.; black). Right panel: representative pictures of some mice upon termination of the experiment. (B) Determination of survivin protein levels in the explanted tumor xenografts. Left: mean levels of all tumor samples; right: representative Western blotting bands of survivin vs. actin for normalization. (C) No changes in mouse body weight upon repeated (see arrows) lipopolyplex treatment.
Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2016 Elsevier Inc. Terms and Conditions

6. Nanomedicine: Nanotechnology, Biology and Medicine 2017 13, 209-218DOI: (10.1016/j.nano.2016.08.005)
Copyright © 2016 Elsevier Inc. Terms and Conditions

7. Supplementary Figure 1
Cellular lipopolyplex uptake, as determined by flow cytometry. Intracellular fluorescence upon incubation of PC-3 cells with lipopolyplexes containing rhodamine-labeled PEI for the indicated time points is shown.
Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2016 Elsevier Inc. Terms and Conditions

8. Supplementary Figure 2
Weights of tumor xenografts after their explantation upon termination of the experiment.
Nanomedicine: Nanotechnology, Biology and Medicine  , DOI: ( /j.nano )
Copyright © 2016 Elsevier Inc. Terms and Conditions